UroToday1d
SUO 2019: Evaluation of Biomarkers 4K Score, SelectMDx and ExoDx™, PSAD, TRUS and MRI for the Detection of High-Grade Prostate Cancer
Washington, DC (UroToday.com) While PSA screening has resulted in decreasing prostate cancer mortality, PSA is also known to be a poorly specific test for the detection of clinically significant ...
UroToday1d
ASCO GU 2025: Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) in the US Community Setting.
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session ...
UroToday1d
ASCO GU 2025: Racial Disparities in Renal Cell Carcinoma Histology and Outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191)
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Rapid Oral Abstract Session C: Renal Cell Cancer. Dr.
UroToday1d
EAU 2020: More Porn, Worse Erectile Function
San Francisco, California (UroToday.com) – A study has shown that the amount of porn a man watches is linked to worse erectile function. Watching porn is also associated with greater dissatisfaction ...
UroToday2d
ASCO GU 2025: Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to the prostate cancer poster session. Dr. Andrei Gafita ...
UroToday2d
ASCO GU 2025: Management of Biochemical Recurrence after Radiation Therapy for Localized Prostate Cancer: Reirradiation, Brachytherapy and SBRT.
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Case-Based Session: Management of Biochemical ...
UroToday2d
ASCO GU 2025: Efficacy of 177Lu-PSMA-617 with or Without Androgen Receptor Pathway Inhibitors for the Treatment of mCRPC: VISION Secondary Analysis
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Omid Yazdanpanah discussing a secondary analysis of the VISION trial assessing the efficacy ...
UroToday2d
ASCO GU 2025: Creative Innovation: Driving Science to Improve Patient-Centered Care
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Keynote Presentation. Dr. William Dahut discussed how ...
UroToday2d
ASCO GU 2025: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate Cancer with Salvage Surgery
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based ...
UroToday2d
Complications - Indwelling Catheters
Catheter related problems due to an indwelling urinary catheter (IUC) have existed as long as urinary catheters have been utilized. This section will review IUC complications: infectious complications ...
UroToday2d
A brief history of urinary catheters
The word “catheter” comes from Greek, meaning “to let or send down.” Catheters were used as early as 3,000 B.C. to relieve painful urinary retention. In those times, many materials were used to form a ...
UroToday2d
ASCO GU 2025: Capturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13th and 15th 2025, was host to the Panning for Gold: ...